Get the Stockscreener App
7.32
0.27%
0.02
Arvinas Inc stock is traded at $7.32, with a volume of 1.41M.
It is up +0.27% in the last 24 hours and down -3.43% over the past month.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
See More
Previous Close:
$7.30
Open:
$7.28
24h Volume:
1.41M
Relative Volume:
0.71
Market Cap:
$537.42M
Revenue:
$161.10M
Net Income/Loss:
$-308.60M
P/E Ratio:
-1.5675
EPS:
-4.67
Net Cash Flow:
$-259.90M
1W Performance:
+3.24%
1M Performance:
-3.43%
6M Performance:
-58.81%
1Y Performance:
-70.04%
1-Day Range:
$7.2601
$7.53
1-Week Range:
$6.955
$7.53
52-Week Range:
$5.90
$29.61
Arvinas Inc Stock (ARVN) Company Profile
Name
Arvinas Inc
Sector
Industry
Phone
203-535-1456
Address
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
7.32 | 526.40M | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-05-25 | Downgrade | Truist | Buy → Hold |
| May-02-25 | Downgrade | Jefferies | Buy → Hold |
| May-02-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-13-25 | Downgrade | Goldman | Buy → Neutral |
| Mar-12-25 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-11-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| Feb-14-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-01-24 | Initiated | Goldman | Buy |
| Dec-19-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-06-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-20-23 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Jan-12-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-22 | Initiated | Barclays | Overweight |
| Jun-21-22 | Initiated | Jefferies | Hold |
| May-09-22 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Apr-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-11-22 | Resumed | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Jan-19-22 | Initiated | Goldman | Buy |
| Dec-07-21 | Initiated | Cowen | Outperform |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-09-21 | Initiated | BofA Securities | Buy |
| May-21-21 | Initiated | UBS | Buy |
| Apr-21-21 | Initiated | Truist | Buy |
| Mar-31-21 | Initiated | BMO Capital Markets | Outperform |
| Dec-14-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-01-20 | Upgrade | Citigroup | Neutral → Buy |
| May-12-20 | Initiated | Oppenheimer | Perform |
| Dec-19-19 | Initiated | H.C. Wainwright | Buy |
| Nov-25-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Upgrade | Goldman | Neutral → Buy |
| Sep-25-19 | Initiated | Wedbush | Outperform |
| Sep-12-19 | Initiated | BMO Capital Markets | Outperform |
| Aug-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-05-19 | Downgrade | Citigroup | Buy → Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-22-18 | Initiated | Citigroup | Buy |
| Oct-22-18 | Initiated | Goldman | Neutral |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
View All
Arvinas Inc Stock (ARVN) Latest News
Arvinas, Pfizer’s Vepdegestrant NDA Accepted by FDA for Breast Cancer Treatment - MSN
What institutional flow reveals about Arvinas Inc.2025 Key Lessons & Fast Exit and Entry Trade Guides - Newser
Published on: 2025-08-20 04:59:17 - Newser
Will Arvinas Inc. stock go up soon2025 Trading Volume Trends & Fast Moving Trade Plans - Newser
What Fibonacci levels say about Arvinas Inc. reboundPortfolio Value Summary & Low Drawdown Investment Ideas - Newser
Technical analysis overview for Arvinas Inc. stockWeekly Trade Analysis & Weekly Chart Analysis and Trade Guides - Newser
Multi asset correlation models including Arvinas Inc.2025 Analyst Calls & Verified Entry Point Detection - Newser
How high can Arvinas Inc. stock goPortfolio Value Report & Weekly Hot Stock Watchlists - Newser
Is Arvinas Inc. forming a reversal patternTrade Risk Summary & Long-Term Safe Investment Plans - Newser
Statistical indicators supporting Arvinas Inc.’s strength2025 Volatility Report & Weekly High Momentum Picks - Newser
Using Ichimoku Cloud for Arvinas Inc. technicals2025 Sector Review & Accurate Entry/Exit Alerts - Newser
What makes Arvinas Inc. stock price move sharplyMarket Movers & Technical Buy Zone Confirmation - Newser
Arvinas Inc. Nearing Breakout Level After Bounce2025 Key Lessons & Fast Gain Swing Alerts - sundaytimes.kr
Arvinas Inc. Consolidation Zone May Signal Accumulation2025 Risk Factors & Technical Pattern Recognition Alerts - kangso.co.kr
Biotech's Big Comeback: 4 Stocks Poised to Ride the Resurgence (MDCX, ARVN, RYTM, ENTA) - MarketScreener
How institutional ownership impacts Arvinas Inc. stockPortfolio Performance Report & Reliable Intraday Trade Plans - Newser
What high frequency data says about Arvinas Inc.Portfolio Return Report & Free Expert Approved Momentum Trade Ideas - Newser
Should you wait for a breakout in Arvinas Inc.Breakout Watch & High Return Trade Guides - Newser
Strategies to average down on Arvinas Inc.July 2025 Setups & Detailed Earnings Play Strategies - Newser
Bank of America Securities Reiterates Buy Rating for Arvinas Holding Company - AInvest
Is Arvinas Inc. a speculative investmentMarket Movers & Daily Risk Controlled Trade Plans - thegnnews.com
Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Arvinas Inc. stock daily chart insightsPortfolio Growth Summary & Stepwise Trade Execution Plans - Newser
Arvinas Inc.’s Price Action Aligns with Quant Signals2025 Key Highlights & Safe Capital Growth Tips - 선데이타임즈
FY2025 EPS Estimates for Arvinas Cut by Cantor Fitzgerald - MarketBeat
Can Arvinas Inc. scale operations efficientlyJuly 2025 Spike Watch & Free Safe Entry Trade Signal Reports - classian.co.kr
HC Wainwright Comments on Arvinas' Q3 Earnings (NASDAQ:ARVN) - MarketBeat
Leerink Partnrs Analysts Cut Earnings Estimates for Arvinas - MarketBeat
Wedbush Has Optimistic Outlook of Arvinas Q3 Earnings - MarketBeat
Arvinas Inc. Stock Approaches Key Moving AverageMarket Growth Summary & Weekly High Momentum Picks - newsimpact.co.kr
Will Arvinas Inc. stock benefit from AI tech trendsForecast Cut & Advanced Swing Trade Entry Plans - Newser
Arvinas’s SWOT analysis: protein degrader stock faces pivotal moment By Investing.com - Investing.com Nigeria
Arvinas’s SWOT analysis: protein degrader stock faces pivotal moment - Investing.com
Arvinas, Inc. (NASDAQ:ARVN) Receives $19.76 Consensus PT from Analysts - MarketBeat
Custom watchlist performance reports with Arvinas Inc.Take Profit & Capital Efficiency Focused Ideas - Newser
Using data filters to optimize entry into Arvinas Inc.Fundamental + Technical Combined Watchlist - Newser
Arvinas (NASDAQ:ARVN) Given New $15.00 Price Target at Guggenheim - MarketBeat
Arvinas (NASDAQ:ARVN) Releases Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
HC Wainwright Has Lowered Expectations for Arvinas (NASDAQ:ARVN) Stock Price - MarketBeat
Is Arvinas Inc. Stock a Good Fit for Conservative InvestorsFree Real Time Stock Movement Analysis - Newser
Metastatic Prostate Cancer Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Merck Sharp & Dohme, Arvinas Androgen Receptor, UNICANCER, Aragon Pharma, Mark Stein, Novartis, Orion - Barchart.com
Pfizer and Arvinas' breast cancer therapy to be reviewed by FDA - MSN
FDA gives Arvinas and Pfizer’s vepdegestrant NDA for breast cancer - Yahoo Finance
Wedbush Issues Positive Forecast for Arvinas Earnings - Defense World
HC Wainwright Comments on Arvinas’ Q3 Earnings (NASDAQ:ARVN) - Defense World
Arvinas, Inc. (NASDAQ:ARVN) Shares Acquired by XTX Topco Ltd - MarketBeat
Arvinas Inc Stock (ARVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):